Publications by authors named "Andy Van Vugt"
Article Synopsis
- - AMG 706 is a new oral drug being tested for its ability to inhibit certain growth factor receptors in patients with advanced solid tumors who have not responded to other treatments.
- - In a phase I study, 71 patients received varying doses of AMG 706, with the maximum-tolerated dose identified as 125 mg daily; side effects included fatigue, diarrhea, nausea, and hypertension.
- - The results indicated that while some patients had a partial response or stable disease, AMG 706 was generally well tolerated, paving the way for further research as a standalone treatment or in combination with other therapies.
